Search | Clinical Trials Finder

Conditions: Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions: Carboplatin, Cisplatin, Docetaxel, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery; Drug · Radiation · Other + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 154
States / cities: Tucson, Arizona • Fort Smith, Arkansas • Palo Alto, California + 111 more

Conditions: Cancer of Larynx
Interventions: Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heart Transplant
Interventions: Preservation of Hearts for Transplantation; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Indianapolis, Indiana • Boston, Massachusetts + 7 more

Conditions: Graft Pancreatitis
Interventions: Two-Layer Method pancreas preservation system drug, Two-Layer Method pancreas preservation system device; Drug · Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Rectal Cancer
Interventions: FOLFOX regimen; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rectal Adenocarcinoma, Rectal Cancer
Interventions: High Rare Dose Rectal Brachytherapy Boost; Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Aurora, Colorado • Rochester, New York • Portland, Oregon

Conditions: Heart Transplant
Interventions: Transplant; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Rectal Adenocarcinoma
Interventions: Capecitabine, Initial Dose of Radiation before Dose Escalation, Cohort A: Dose Escalation Radiation, Cohort B: Dose Escalation Radiation, Cohort C: Dose Escalation Radiation, FOLFOX; Drug · Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Rectal Cancer
Interventions: FOLFOXIRI, FOLFOX regimen, XELOX, IMRT; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Heart Failure
Interventions: Organ Care System, Cold Cardioplegia Solution; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Indianapolis, Indiana • Boston, Massachusetts + 3 more

Conditions: Lung Preservation
Interventions: OCS Lung, Cold flush and storage; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more

Conditions: Urothelial Carcinoma Bladder
Interventions: Reproductive organ sparing radical cystectomy, Radical cystectomy; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Head and Neck Cancer
Interventions: Induction chemotherapy, cisplatin, fluorouracil, low-LET cobalt-60 gamma ray therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 18
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 10 more

Conditions: Lung Transplant, Organ Preservation
Interventions: Lung transplantation after 10°C donor lung preservation, Lung transplantation after standard ice cooler donor lung preservation; Device
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years to 80 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Phoenix, Arizona • San Francisco, California • Coral Gables, Florida + 4 more

Conditions: Organ Transplantation From Brain-dead Donors
Interventions: Cold isotonic fluid and central venous hypothermia catheter; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Transplant
Interventions: OCS Lung Preservation; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more

Conditions: Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Interventions: Gemcitabine, Cisplatin, Cemiplimab, Fianlimab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastrointestinal Malignancies
Interventions: The Functional Assessment of Cancer Therapy- Colorectal; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Boston, Massachusetts • Newton, Massachusetts

Conditions: Colorectal Cancer, Gastroesophageal Cancer
Interventions: nivolumab, ipilimumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rectum Cancer, Adenocarcinoma
Interventions: Adaptive Radiotherapy Boost; Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease
Interventions: Planned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Organ Preservation
Interventions: Sub-Normothermic Machine Preservation and Assessment; Other
Lead sponsor: 34 Lives, PBC; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more

Conditions: Head and Neck Cancer
Interventions: carboplatin, paclitaxel, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 47
States / cities: Jacksonville, Florida • Lakeland, Florida • Chicago, Illinois + 28 more

Conditions: Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy; Drug · Radiation · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 783 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 679
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more

Search by objective public record fields.

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

International EXPAND Heart Pivotal Trial

Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation

Organ Preservation in Early Rectal Cancer Patients

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Donor After Circulatory Death Heart CAP Trial

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation

International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue

10°C vs 4°C Lung Preservation RCT

Cooling to Optimize Organ Life in Donor Study

International EXPAND Lung Pivotal Trial

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Adaptive Radiation Boost for Rectal Cancer

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation